Benzinga.com · 9h
'Miracle' Weight Loss Drug Ozempic To Enter US Price Negotiations Within A Year, Novo Nordisk CEO Says Ahead Of Senate Hearing
Novo Nordisk 's NVO CEO Lars Fruergaard Jorgensen, has revealed that their diabetes medication and often hailed as a “miracle” weight loss drug, Ozempic will soon be eligible for U.S. government price negotiations, potentially within the next year.
Bloomberg L.P. · 23h
Novo CEO Blames Ozempic’s High Cost on Drug Middlemen’s Tactics
Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen will use a familiar argument to defend the US prices of blockbuster drugs Ozempic and Wegovy when he appears Tuesday before a congressional committee led by Senator Bernie Sanders: It’s the middlemen.
FiercePharma · 5h
Novo Nordisk CEO prepares to defend Ozempic, Wegovy US pricing at Senate hearing
After circling Novo Nordisk and its high GLP-1 drug prices for months, Sen. | Ahead of a hearing on Ozempic and Wegovy prices, prepared remarks from Novo CEO Lars Fruergaard Jørgensen shine a light on the larger U.
Reuters · 22h
Novo says Ozempic to be eligible for US price negotiations in less than a year
Novo Nordisk's blockbuster diabetes drug Ozempic will be eligible for U.S. government's price negotiations in less than a year based on current criteria, the Danish drugmaker's CEO Lars Fruergaard Jorgensen said in his written testimony on Monday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results